Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Jan 31;4:3. doi: 10.1186/s43556-023-00114-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — DDB1 is PARylated in response to DNA damage and the inhibition of PARG impairs DSBs repair in HCC. a Coverage and peptides number of PARylated DDB1 detected by LC–MS. b The Hep3B cells were lysed and immunoprecipitated with Af1521 macrodomain (PAR/MAR) affinity resins or an anti-DDB1 antibody followed by western blotting with an anti-DDB1 antibody or an anti-PAR antibody at the indicated time points after X-Ray treatment (4 Gy). c Colony-formation assays were applied to assess the survival of Hep3B and HCCLM3 cells treated with X-Ray (1 Gy), with PARG inhibitor (1 μM). d Western blotting assays for the effect of PARG inhibition (2 μM PDD00017273) on the γH2AX expression level in Hep3B and HCCLM3 cells at the indicated time points after X-Ray treatment (4 Gy)